Press Releases | Gilead - Gilead Sciences
WEBJul 25, 2024 · Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024. January 22, 2024. Gilead Provides Update on Phase 3 EVOKE-01 Study. Read the latest news about Gilead's work in COVID-19, HIV, viral hepatitis, cancer and other areas.
Newsroom | Gilead - Gilead Sciences
WEBRecent Press Releases. September 12, 2024. Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial. September 10, 2024. Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies.
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy …
WEBFOSTER CITY, Calif., June 20, 2024 -- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial...
Gilead Sciences Announces Fourth Quarter and Full Year 2023 …
WEBFeb 6, 2024 · Biktarvy® (bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 7% to $3.1 billion in the fourth quarter 2023 compared to the same period in 2022, primarily reflecting higher demand, partially offset by lower average realized price due to channel mix.
Gilead Sciences Announces Fourth Quarter and Full Year 2022 …
WEBFeb 2, 2023 · Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results. Product Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2022. Biktarvy Sales Increased Year-Over-Year by 20% for Full Year 2022. Oncology Sales Increased Year-Over-Year by 71% for Full Year 2022.
Gilead to Present New Trodelvy Data at the IASLC 2024 World …
WEBSep 5, 2024 · Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast, bladder and lung cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload.
Gilead Sciences Announces Second Quarter 2022 Financial Results
WEBTotal second quarter 2022 revenue increased 1% to $6.3 billion compared to the same period in 2021, primarily due to increased sales in HIV and oncology products, offset partially by decreased sales of Veklury® (remdesivir) and hepatitis C …
Gilead Sciences Announces Third Quarter 2023 Financial Results
WEBNov 7, 2023 · Third Quarter 2023 Financial Results. Total third quarter 2023 revenue of $7.1 billion was flat compared to the same period in 2022, primarily driven by increased sales in Oncology and HIV, offset by lower Veklury® (remdesivir) and chronic hepatitis C virus (“HCV”) product sales.
Gilead PrEP lenacapavir succeeds in Phase 3 trial - CNBC
WEBJun 20, 2024 · Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
Gilead Sciences Appoints Stacey Ma PhD as Executive Vice …
WEBJun 2, 2022 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Stacey Ma, PhD will join the company as Executive Vice President, Pharmaceutical Development and Manufacturing, and will become a member of the company’s senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O’Day. Dr ...
Skip to content